Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Broader search needed for successful management of eosinophilic gastritis

The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with eosinophilic gastritis.

16 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Study shows how blood makes the brain’s immune cells toxic

In patients with neurological diseases like Alzheimer's disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment.

8 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

MFAP5, a microfibril-associated protein, unveiled as key player in scar formation and wound healing

MFAP5, a microfibril-associated protein, plays a significant role in wound healing by regulating fibroblast function, collagen deposition, and angiogenesis, suggesting its potential as a modulator of scar formation.

1 Jun 2023

Mental health profoundly impacts inflammatory responses in the body

Study uncovered mechanisms by which psychological stress affects bowel inflammation.

30 May 2023

"Smart" sutures can detect inflammation and release drugs

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

16 May 2023

Targeting the hemoglobin problem in sickle cell disease using a new drug

A class of drugs used for their ability to stop tumor cells from dividing is now under study for their potential to reduce the pain and damage caused by sickle cell disease, investigators report.

11 May 2023

UCF researcher develops a new, more precise treatment for acute respiratory viral infections

A University of Central Florida College of Medicine researcher has developed a new, more precise treatment for a major cause of illness around the world each year -; acute respiratory viral infections.

9 May 2023

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Researchers highlighted the pace of development of COVID-19 therapies during the pandemic and the challenges that hinder the widespread availability of anticoronavirals.

8 May 2023

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

Scientists discuss hantavirus infections, which are a type of viral hemorrhagic fever that can be transmitted to humans through exposure to infected rodents in endemic areas.

30 Apr 2023

Research identifies Th1 memory CD4+ T cells as key to protect against emerging poxvirus skin infections

Researchers demonstrate that T helper 1 effector memory cluster of differentiation 4 T cells provide immunity against poxviruses

27 Apr 2023

Bioengineered drug candidate can counter S. aureus infection in early tests

Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

24 Apr 2023

Antibody combination strongly protects high-risk people with early COVID-19 symptoms, trial shows

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

20 Apr 2023

The economic burden of RSV infections in low and middle-income countries

Researchers discuss the cost-of-illness associated with RSV infections among children in low and middle-income countries.

6 Apr 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

Monoclonal Antibody News and Research

Further Reading

Broader search needed for successful management of eosinophilic gastritis

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Study shows how blood makes the brain’s immune cells toxic

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

MFAP5, a microfibril-associated protein, unveiled as key player in scar formation and wound healing

Mental health profoundly impacts inflammatory responses in the body

"Smart" sutures can detect inflammation and release drugs

Targeting the hemoglobin problem in sickle cell disease using a new drug

UCF researcher develops a new, more precise treatment for acute respiratory viral infections

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

Research identifies Th1 memory CD4+ T cells as key to protect against emerging poxvirus skin infections

Bioengineered drug candidate can counter S. aureus infection in early tests

Antibody combination strongly protects high-risk people with early COVID-19 symptoms, trial shows

The economic burden of RSV infections in low and middle-income countries

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

mAb therapy reduces risk of hospitalization and death against Alpha, Delta, and Omicron variants

Omicron BA.5 variant demonstrates increased neuroinvasiveness and pathogenicity in mice

Probiotic E. coli secretes proteins of therapeutic value into its surroundings

Lab-made antibodies may be able to cure people infected with yellow fever

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News